ResMed Inc. revenue by segment RMD

ResMed Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2026, which ended Jun 30, 2026 was Sleep And Breathing Health at $5.0 billion, 88% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line
FY 2027
Sep 30, 2026
FY 2026
Jun 30, 2026
FY 2025
Jun 30, 2025
FY 2024
Jun 30, 2024
FY 2023
Jun 30, 2023
FY 2022
Jun 30, 2022
FY 2021
Jun 30, 2021
FY 2020
Jun 30, 2020
FY 2019
Jun 30, 2019
FY 2018
Jun 30, 2018
FY 2017
Jun 30, 2017
Revenue
5,733
5,653
5,146
4,685
4,223
3,578
3,197
2,957
2,607
2,340
2,067
Sleep And Breathing Health
5,068
+10.0%
share 88.4%
4,978
+10.5%
share 88.0%
4,505
+9.8%
share 87.5%
4,101
+10.1%
share 87.5%
3,725
+17.2%
share 88.2%
3,177
+12.5%
share 88.8%
2,823
+8.5%
share 88.3%
2,602
+11.7%
share 88.0%
2,331
+6.8%
share 89.4%
2,183
share 93.3%
—
Residential Care Software
665
+2.1%
share 11.6%
676
+5.4%
share 12.0%
641
+9.8%
share 12.5%
584
+17.3%
share 12.5%
498
+24.2%
share 11.8%
401
share 11.2%
—
—
—
—
—
Software As A Service
—
—
—
—
—
401
+7.3%
share 11.2%
374
+5.3%
share 11.7%
355
+28.6%
share 12.0%
276
+75.7%
share 10.6%
157
share 6.7%
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
RMD (NYSE), RSMDF (OTC)
Fiscal year ends
June 30
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Large accelerated filer
SEC CIK
943819

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.